The cost-effectiveness of screening men who have sex with men for rectal chlamydial and gonococcal infection to prevent HIV infection

Sexually Transmitted Diseases

Volumn 40, Issue 5, 2013, Pages 366-371

  Chesson, Harrell W ^a   Bernstein, Kyle T ^b   Gift, Thomas L ^a   Marcus, Julia L ^b   Pipkin, Sharon ^b   Kent, Charlotte K ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE PREDISPOSITION; GONORRHEA; HIDDEN MARKOV MODEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; NEISSERIA GONORRHOEAE; QUALITY ADJUSTED LIFE YEAR; RECTUM DISEASE; SCREENING; UNITED STATES;

ADULT; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; COST-BENEFIT ANALYSIS; GONORRHEA; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; INCIDENCE; MALE; MARKOV CHAINS; MASS SCREENING; NEISSERIA GONORRHOEAE; QUALITY-ADJUSTED LIFE YEARS; QUESTIONNAIRES; RECTAL DISEASES; SAN FRANCISCO; SEXUAL BEHAVIOR;

EID: 84876283374     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e318284e544     Document Type: Article

References (35)

1. Bernstein KT, Marcus JL, Nieri G, et al. Rectal gonorrhea and chlamydia reinfection is associated with increased risk of HIV serocon-version. J Acquir Immune Defic Syndr 2010; 53:537-543.
2. Craib KJ, Meddings DR, Strathdee SA, et al. Rectal gonorrhoea as an independent risk factor for HIV infection in a cohort of homosexual men. Genitourin Med 1995; 71:150-154.
3. Zetola NM, Bernstein KT, Wong E, et al. Exploring the relationship between sexually transmitted diseases and HIVacquisition by using different study designs. J Acquir Immune Defic Syndr 2009; 50:546-551.
4. Annan NT, Sullivan AK, Nori A, et al. Rectal chlamydiaVa reservoir of undiagnosed infection in men who have sex with men. Sex Transm Infect 2009; 85:176-179.
5. Gunn RA, O'Brien CJ, Lee MA, et al. Gonorrhea screening among men who have sex with men: value of multiple anatomic site testing, San Diego, California, 1997-2003. Sex Transm Dis 2008; 35:845-848.
6. Kent CK, Chaw JK, Wong W, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clin Infect Dis 2005; 41:67-74.
7. Marcus JL, Bernstein KT, Kohn RP, et al. Infections missed by urethral-only screening for chlamydia or gonorrhea detection among men who have sex with men. Sex Transm Dis 2011; 38:922-924.
8. Marcus JL, Bernstein KT, Stephens SC, et al. Sentinel surveillance of rectal chlamydia and gonorrhea among malesVSan Francisco, 2005-2008. Sex Transm Dis 2010; 37:59-61.
9. Mimiaga MJ, Mayer KH, Reisner SL, et al. Asymptomatic gonorrhea and chlamydial infections detected by nucleic acid amplification tests among Boston area men who have sex with men. Sex Transm Dis 2008; 35:495-498.
10. Young H, Manavi K, McMillan A. Evaluation of ligase chain reaction for the non-cultural detection of rectal and pharyngeal gonorrhoea in men who have sex with men. Sex Transm Infect 2003; 79:484-486.
11. Workowski KA, Berman S. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1-110.
12. Hoover KW, Butler M, Workowski K, et al. STD screening of HIV-infected MSM in HIV clinics. Sex Transm Dis 2010; 37:771-776.
13. HIV Epidemiology Section, San Francisco Department of Public Health. HIV/AIDS Epidemiology Annual Report. San Francisco, CA: San Francisco Department of Public Health, 2011.
14. Althaus CL, Heijne JCM, Low N. Towards more robust estimates of the transmissibility of Chlamydia trachomatis. Sex Transm Dis 2012; 39:402-404.
15. Althaus CL, Heijne JCM, Roellin A, et al. Transmission dynamics of Chlamydia trachomatis affect the impact of screening programmes. Epidemics 2010; 2:123-131.
16. Schachter J, Moncada J, Liska S, et al. Nucleic acid amplification tests in the diagnosis of chlamydial and gonococcal infections of the oropharynx and rectum in men who have sex with men. Sex Transm Dis 2008; 35:637-642.
17. Turner KME, Adams EJ, LaMontagne DS, et al. Modelling the effectiveness of chlamydia screening in England. Sex Transm Infect 2006; 82:496-502.
18. Begley CE, McGill L, Smith PB. The incremental cost of screening, diagnosis, and treatment of gonorrhea and chlamydia in a family planning clinic. Sex Transm Dis 1989; 16:63-67.
19. Desai K, Sansom SL, Ackers ML, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 2008; 22:1829-1839.
20. Hutchinson AB, Farnham PG, Dean HD, et al. The economic burden of HIV in the United States in the era of highly active antiretro-viral therapy: Evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr 2006; 43:451-457.
21. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care 2006; 44:990-997.
22. Steece R. Determination of laboratory costs: Or what does it cost to run a nucleic acid amplification test (NAAT). Presented at: 2008 American Society for Microbiology 108th General Meeting; 2008; Boston.
23. Thompson Healthcare. 2008 Red Book: Pharmacy's Fundamental Reference. Montvale, NJ: Thompson Healthcare, 2008.
24. Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50, 000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008; 8:165-178.
25. Tengs TO. Cost-effectiveness versus cost-utility analysis of interventions for cancer: Does adjusting for health-related quality of life really matter? Value Health 2004; 7:70-78.
26. Hu D, Hook EW 3rd, Goldie SJ. Screening for Chlamydia trachomatis in women 15 to 29 years of age: A cost-effectiveness analysis. Ann Intern Med 2004; 141:501-513.
27. Gift TL, Gaydos CA, Kent CK, et al. The program cost and cost-effectiveness of screening men for chlamydia to prevent pelvic inflammatory disease in women. Sex Transm Dis 2008; 35:S66-S75.
28. Maciosek MV, Edwards NM, Coffield AB, et al. Priorities among effective clinical preventive services: Results of a systematic review and analysis. Am J Prev Med 2006; 31:52-61.
29. Cohen CR, Plummer FA, Mugo N, et al. Increased interleukin-10 in the endocervical secretions of women with non-ulcerative sexually transmitted diseases: A mechanism for enhanced HIV-1 transmission? AIDS 1999; 13:327-332.
30. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: Implications for prevention of sexual transmission of HIV-1. Lancet 1997; 349:1868-1873.
31. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: The contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75:3-17.
32. Hanson J, Posner S, Hassig S, et al. Assessment of sexually transmitted diseases as risk factors for HIV seroconversion in a New Orleans sexually transmitted disease clinic, 1990-1998. Ann Epidemiol 2005; 15:13-20.
33. Rottingen JA, Cameron DW, Garnett GP. A systematic review of the epidemiologic interactions between classic sexually transmitted diseases and HIVVHow much really is known? Sex Transm Dis 2001; 28:579-597.
34. Ward H, Ronn M. Contribution of sexually transmitted infections to the sexual transmission of HIV. Curr Opin HIV AIDS 2010; 5:305-310.
35. Centers for Disease Control and Prevention. High-Impact HIV Prevention. CDC's Approach to Reducing HIV Infections in the United States. Atlanta, GA: CDC, 2011.